Hepatitis B Control
Strategic Information and Country Profiles

World Health Organization
Western Pacific Region
Hepatitis B Control
Strategic Information and Country Profiles
# CONTENTS

1. **Abbreviations**  IV
2. **Context**  I
3. **Regional Progress: Hepatitis B Control Milestones**  II
4. **Regional Progress: Chronic Hepatitis B Virus Prevalence**  IV
6. **Regional Progress: Status of the 2012 Hepatitis B Control Milestone**  VI
7. **Country Profiles**
   - American Samoa  8
   - Australia  9
   - Brunei Darussalam  10
   - Cambodia  11
   - China  12
   - Hong Kong (China)  13
   - Macao (China)  14
   - Cook Islands  15
   - Fiji  16
   - French Polynesia  17
   - Guam  18
   - Japan  19
   - Kiribati  20
   - Lao People’s Democratic Republic  21
   - Malaysia  22
   - Marshall Islands  23
   - Federated States of Micronesia  24
   - Mongolia  25
   - Nauru  26
   - New Caledonia  27
   - New Zealand  28
   - Niue  29
   - Northern Mariana Islands  30
   - Palau  31
   - Papua New Guinea  32
   - Philippines  33
   - Republic of Korea  34
   - Samoa  35
   - Singapore  36
   - Solomon Islands  37
   - Tokelau  38
   - Tonga  39
   - Tuvalu  40
   - Vanuatu  41
   - Viet Nam  42
   - Wallis and Futuna  43
## ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AusAID</td>
<td>Australian Agency for International Development</td>
</tr>
<tr>
<td>BD</td>
<td>Birth Dose</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>DHS</td>
<td>Demographic and Health Survey</td>
</tr>
<tr>
<td>DTP3</td>
<td>Third dose of diphtheria-pertussis-tetanus vaccine</td>
</tr>
<tr>
<td>GAVI</td>
<td>Global Alliance for Vaccines and Immunization</td>
</tr>
<tr>
<td>HB</td>
<td>Hepatitis B</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B virus</td>
</tr>
<tr>
<td>HepB</td>
<td>Hepatitis B</td>
</tr>
<tr>
<td>HepB3</td>
<td>Third dose of hepatitis B vaccine</td>
</tr>
<tr>
<td>HBsAg</td>
<td>Hepatitis B surface antigen (a marker of hepatitis B infection)</td>
</tr>
<tr>
<td>JRF</td>
<td>Joint reporting form</td>
</tr>
<tr>
<td>NZAID</td>
<td>New Zealand Agency for International Development</td>
</tr>
<tr>
<td>SBA</td>
<td>Skilled birth attendant</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>UNICEF</td>
<td>United Nations Children’s Fund</td>
</tr>
</tbody>
</table>
Remarkable progress has been made in controlling hepatitis B infection in the Western Pacific Region. In 2005 the Regional Committee for the Western Pacific made a momentous decision to adopt the world’s first regional hepatitis B control goal. Resolution WPR/RC56.8 set a goal of less than 1% hepatitis B prevalence among children with a milestone target of less than 2% prevalence by 2012. In 2012 the Region made history by achieving that milestone. The countries and areas of the Western Pacific Region have proven that a well-planned programme including evidence-based policies and careful performance measurement is a formula for success.

This document provides an overview of the hepatitis B control programme in the Western Pacific Region, and hepatitis B data profiles for the 36 countries and areas of the Region. The profiles include demographic data, vaccination policies, childbirth delivery types, reported vaccination coverage from 2008–2012, vaccination coverage and seroprevalence survey summaries, and the status of hepatitis B control verification. We are hopeful that this easy-to-read snapshot of up-to-date data by country will be a useful tool for decision-makers in sustaining and increasing the important gains in hepatitis B control in the Western Pacific Region.

The Region has proven that suffering and death due to hepatitis B infection need not continue. Currently nine countries and areas have been verified as having reached the goal of less than 1% hepatitis B prevalence among five-year-old children. Let us continue to work together to ensure that all countries and areas achieve and sustain the goal of less than 1% hepatitis B prevalence among children, and that hepatitis B infection becomes a thing of the past.
Plasma-derived hepatitis B vaccine becomes the first ever cancer preventing vaccine licensed (the recombinant hepatitis B vaccine in use today was licensed in 1986).

The World Health Organization recommends hepatitis B vaccination for all infants.

AusAID, NZAID, WHO and UNICEF implement a project to increase hepatitis B vaccination in Pacific island countries.

GAVI support for hepatitis B vaccine introduction becomes available for GAVI-eligible countries.

All countries and areas in the Region include hepatitis B vaccination as part of their national immunization policies (Japan has targeted vaccination).

All countries and areas in the Region adopt hepatitis B birth dose vaccination for all newborn infants with the exception of Japan and New Zealand, which conduct targeted vaccination.
**Partners**

- Global action or recommendation
- Regional action or recommendations
- Country or regional progress

**Key Milestones**

**Hepatitis B (HB)**

- Plasma-derived hepatitis B vaccine becomes the first ever cancer preventing vaccine licensed (the recombinant hepatitis B vaccine in use today was licensed in 1986).

**AusAID, NZAID, WHO and UNICEF implement a project to increase hepatitis B vaccination in Pacific island countries.**

**GAVI support for hepatitis B vaccine introduction becomes available for GAVI-eligible countries.**

**WHO recommends hepatitis B birth dose vaccination for all newborn infants.**

**Hong Kong (China) and Malaysia verified as having reached the 1% hepatitis B control goal. Tonga verified as having reached the 2% hepatitis B control milestone.**

**The Western Pacific Region as a whole and at least 30 countries and areas meet the 2% hepatitis B milestone. Australia, China, Mongolia and New Zealand verified as having reached the 1% hepatitis B control. Palau verified as having reached the 1% hepatitis B control goal.**

**The Western Pacific Region holds discussions on setting the target year for the 1% goal.**

**Macao (China) and the Republic of Korea and are the first countries and areas officially verified as having reached the 1% hepatitis B control goal.**

**The Victorian Infectious Diseases Reference Laboratory (VIDRL) becomes the hepatitis B reference laboratory for the Western Pacific Region.**

**CDC supports WHO Regional Office for the Western Pacific in hepatitis B control.**

**WHO**

- recommends hepatitis B birth dose vaccination for all newborn infants.

**The Victorian Infectious Diseases Reference Laboratory (VIDRL) becomes the hepatitis B reference laboratory for the Western Pacific Region.**

**CDC supports WHO Regional Office for the Western Pacific in hepatitis B control.**

**Hong Kong (China) and Malaysia verified as having reached the 1% hepatitis B control goal. Tonga verified as having reached the 2% hepatitis B control milestone.**

**The Western Pacific Region sets a goal to reduce hepatitis B infection among children to less than 1% with a milestone of less than 2% by 2012.**

**All countries and areas in the Region adopt hepatitis B birth dose vaccination for all newborn infants with the exception of Japan and New Zealand, which conduct targeted vaccination.**

**The World Health Organization recommends hepatitis B vaccination for all infants.**

**Macao (China) and the Republic of Korea and are the first countries and areas officially verified as having reached the 1% hepatitis B control goal.**

**100%**

**1% 100%**
Regional Progress
Chronic Hepatitis B Virus (HBV) Prevalence in Children

Chronic HBV prevalence before vaccine

- >6% prevalence
- >2% - 6% prevalence
- <2% prevalence

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement © WHO Regional Office for the Western Pacific 2009. All rights reserved.
Regional Progress
Hepatitis B Vaccination Coverage, 1990–2011

Year

% Vaccination coverage


Timely birth dose coverage (<24 hours) 3-Dose hepatitis B coverage

6
Regional Progress
Status of the 2012 Hepatitis B Control Milestone*

- Mongolia
- China
- Japan
- Republic of Korea
- Lao People’s Democratic Republic
- Cambodia
- Viet Nam
- Singapore
- Malaysia
- Viet Nam
- Macao (China)
- Hong Kong (China)
- Philippines
- Commonwealth of Northern Mariana Islands
- Marshall Islands
- Federated States of Micronesia
- Guam
- Marshall Islands
- Solomon Islands
- Wallis and Futuna
- Vanuatu
- Fiji
- American Samoa
- Cook Islands
- Tahiti
- Niue
- Tuvalu
- Tokelau
- Nauru
- Palau
- Papua New Guinea
- Nauru
- Kiribati
- Solomon Islands
- New Caledonia
- Vanuatu
- New Zealand
- Tonga
- Federated States of Micronesia
- Marshall Islands
- American Samoa
- Cook Islands
- French Polynesia
- samo
- Norfolk Island
- Christmas Island
- Christmas Island
- Lord Howe Island
- Christmas Island
- Christmas Island

*Milestone: <2% childhood hepatitis B infection prevalence

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries. Dotted lines on maps represents approximate border lines for which there may not yet be full agreement © WHO Regional Office for the Western Pacific 2009. All rights reserved.
**Demographics**

- Total population (2012): 70,680
- Births (2012): 1,375
- Surviving infants (2012): 1,359
- Urban population (2012): 93%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1986–1987
- HepB birth dose introduced: not reported
- Current schedule: 0, 1 month, 12 months
- HepB3 type: Monovalent

**Neonatal deliveries**

- Health facility: 99.0%
- Home with SBA: 1.0%
- Home with no SBA: 0%
- Unknown: 0%

**Reported hepatitis B vaccination coverage**

- Timely HepB BD: 94% (2012)
- HepB3: 90%–94% (2012)
- Any HepB BD: 80%–89% (2012)
- DTP3: 50%–79% (2012)

**Districts by coverage categories**

<table>
<thead>
<tr>
<th>Year</th>
<th>Districts 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>100%</td>
</tr>
</tbody>
</table>

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD</th>
<th>HepB3</th>
<th>DTP3</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1990</td>
<td>National</td>
<td>3–4 years</td>
<td>95</td>
<td>not reported</td>
<td>82%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>1995</td>
<td>National</td>
<td>7–8 years</td>
<td>432</td>
<td>75%</td>
<td>91%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>1996</td>
<td>National</td>
<td>7–8 years</td>
<td>435</td>
<td>not reported</td>
<td>87%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Tutuila</td>
<td>3–4 years</td>
<td>Community based</td>
<td>93</td>
<td>2.2%</td>
<td>Mahoney JID 2009</td>
</tr>
<tr>
<td>1995</td>
<td>Nationwide</td>
<td>7–8 years</td>
<td>Community based</td>
<td>432</td>
<td>0.5%</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2011</td>
<td>Nationwide</td>
<td>6 years</td>
<td>School based</td>
<td>562</td>
<td>0.20%</td>
<td>PRELIMINARY DATA</td>
</tr>
</tbody>
</table>

**WHO verification**

- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

**Abbreviations**

- DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**

- UN, UNICEF and WHO
- HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

- **Total population (2012):** 22,918,688
- **Births (2012):** 310,837
- **Surviving infants (2012):** 305,841
- **Urban population (2012):** 89%

### Hepatitis B vaccine

- **HepB3 introduced nationwide:** 2000
- **HepB birth dose introduced:** 2000
- **Current schedule:** 0, 2 months, 4 months, 6 months
- **HepB3 type:** DTP-Hib-HepB-IPV

### Neonatal deliveries

- **HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.**

### Vaccination coverage surveys

- **Survey year:** 2007
- **Location:** National
- **Ages enrolled:** 12 months
- **Sample size:** 280,874
- **HepB BD:** not reported
- **HepB3:** 94%
- **DTP3:** 92%
- **Reference/Notes:** From National Health Insurance covering 99% of population

### Hepatitis B serological surveys

- **Survey year:** 2002
- **Location:** Nationwide
- **Ages enrolled:** 1–9 years
- **Sampling base:** Hospital based
- **Sample size:** 249
- **HBsAG prevalence (95% CI):** 0.4% (0.0% – 2.2%)
- **Reference/Notes:** Gidding Vaccine 2007

### WHO verification

- **Status of verifying prevalence targets:**
  - **Verification started:** June 2012
  - **Decision:** <1% in children
  - **Decision date:** December 2012

---

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** UN, UNICEF and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**BRUNEI DARUSSALAM**

### Demographics

- Total population (2012): 412,892
- Births (2012): 7,607
- Surviving infants (2012): 7,597
- Urban population (2012): 76%

### Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-Hib-HepB-IPV

### Neonatal deliveries

- 99.80%
- 0.10% Health facility
- 0.10% Home with SBA
- 99.80% Home with no SBA
- Unknown

### Reported hepatitis B vaccination coverage

- Vaccination coverage (%)
  - 2012: 99.80%
  - 2011: 99.80%
  - 2010: 99.80%
  - 2009: 99.80%
  - 2008: 99.80%

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Districts by coverage categories*

- Timely HepB BD
- HepB3
- Any HepB BD

### Vaccination coverage surveys

- Total population (2012): 412,892
- Births (2012): 7,607
- Surviving infants (2012): 7,597
- Urban population (2012): 76%

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence [95% CI]</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>8–9 years</td>
<td>School based</td>
<td>4513</td>
<td>not reported</td>
<td>MoH 2011 prelim data</td>
</tr>
</tbody>
</table>

### WHO verification

- Verification started: December 2012
- Decision: 1%
- Decision date: June 2013

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** UN, UNICEF and WHO

1 HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population [2012]</td>
<td>14,478,320</td>
</tr>
<tr>
<td>Births [2012]</td>
<td>315,909</td>
</tr>
<tr>
<td>Surviving infants [2012]</td>
<td>303,244</td>
</tr>
<tr>
<td>Urban population [2012]</td>
<td>20%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

- **HepB3** introduced nationwide: 2005
- **HepB birth dose introduced**: 2005
- **Current schedule**: 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type**: DTP-Hib-HepB

### Neonatal deliveries

- Health facility: 54.0%
- Home with SBA: 29.0%
- Home with no SBA: 17.0%
- Unknown: 9.0%

### Reported hepatitis B vaccination coverage

- **Timely HepB BD**: Birth dose within 24 hours
- **HepB3**: at least 3 doses of hepatitis B vaccine
- **Any HepB BD**: DTP-Hib-HepB

### Districts by coverage categories*

- 2012
  - Less than 50%
  - 50%–79%
  - 80%–89%
  - 90%–94%
  - Greater than 94%

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>12–24 months</td>
<td>1517</td>
<td>not reported</td>
<td>not reported</td>
<td>78%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2010</td>
<td>National</td>
<td>12–24 months</td>
<td>1614</td>
<td>73%</td>
<td>84%</td>
<td>not reported</td>
<td>DHS Survey: birth dose by 12M</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>Kg Chhnang</td>
<td>9–17 months</td>
<td>Hospital based</td>
<td>900</td>
<td>2.7%</td>
<td>Report MoH/PATH/AIHI</td>
</tr>
<tr>
<td>2006</td>
<td>Nationwide</td>
<td>5 years</td>
<td>Community based</td>
<td>1558</td>
<td>3.5% (2.4% – 4.6%)</td>
<td>Soeung AMTH 2009</td>
</tr>
<tr>
<td>2011</td>
<td>Urban, Rural, Remote</td>
<td>4–5 years</td>
<td>Community based</td>
<td>2429</td>
<td>0.3%, 1.4%, 3.4%</td>
<td>PRELIMINARY DATA</td>
</tr>
</tbody>
</table>

### WHO verification

- **Verification started**: pending
- **Decision**: n.a.
- **Decision date**: n.a.

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: UN, UNICEF and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### CHINA

#### Demographics
- **Total population (2012):** 1,353,600,687
- **Births (2012):** 16,209,546
- **Surviving infants (2012):** 16,068,111
- **Urban population (2012):** 50%

#### Hepatitis B vaccine
- **HepB3 introduced nationwide:** 1992
- **HepB birth dose introduced:** 1992
- **Current schedule:** 0, 1 months, 6 months
- **HepB3 type:** Monovalent

#### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>1 year</td>
<td>3636</td>
<td>93%</td>
<td>83%</td>
<td>ng</td>
<td>Liang JID 2009; 2005 birth cohort</td>
</tr>
</tbody>
</table>

#### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>Nationwide</td>
<td>1–4 years</td>
<td>Community based</td>
<td>16376</td>
<td>1.0% (0.8% – 1.2%)</td>
<td>Liang Vaccine 2009</td>
</tr>
<tr>
<td>2006</td>
<td>Nationwide</td>
<td>5 years</td>
<td>Community based</td>
<td>2215</td>
<td>1.1% (0.4% – 1.8%)</td>
<td>Liang JID 2009</td>
</tr>
<tr>
<td>2006</td>
<td>Nationwide</td>
<td>6 years</td>
<td>Community based</td>
<td>2356</td>
<td>0.9% (0.4% – 1.5%)</td>
<td>Liang JID 2009</td>
</tr>
</tbody>
</table>

#### Districts by coverage categories*

<table>
<thead>
<tr>
<th>Timely HepB BD</th>
<th>HepB3</th>
<th>Any HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–50%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50%–79%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80%–89%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90%–94%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;94%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Abbreviations:
- DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

#### WHO verification
- **Status of verifying prevalence targets:**
  - Verification started: February 2012
  - Decision: <1% in children
  - Decision date: June 2012

---

1. HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.

---

**Sources:** UN, UNICEF, and WHO
**Demographics**

- **Total population (2012)**: 7,196,450
- **Births (2012)**: 63,272
- **Surviving infants (2012)**: 61,843
- **Urban population (2012)**: 95%

**Hepatitis B vaccine**

- **HepB3 introduced nationwide**: 1988
- **HepB birth dose introduced**: 1988
- **Current schedule**: 0, 1 months, 6 months
- **HepB3 type**: Monovalent

**Neonatal deliveries**

- 100.0%

**Reported hepatitis B vaccination coverage**

- 2008: 100%
- 2009: 100%
- 2010: 100%
- 2011: 100%
- 2012: 100%

**Districts by coverage categories***

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50%</td>
<td>%</td>
</tr>
<tr>
<td>50%–79%</td>
<td>%</td>
</tr>
<tr>
<td>80%–89%</td>
<td>%</td>
</tr>
<tr>
<td>90%–94%</td>
<td>%</td>
</tr>
<tr>
<td>&gt;94%</td>
<td>%</td>
</tr>
</tbody>
</table>

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>2–5 years</td>
<td>6248</td>
<td>not reported</td>
<td>≥99.5%</td>
<td>&gt;99.8%</td>
<td>MoH HOK 2011</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>Nationwide</td>
<td>1–4 years</td>
<td>Laboratory based</td>
<td>196</td>
<td>1%</td>
<td>MoH HOK 2011</td>
</tr>
<tr>
<td>2009</td>
<td>Nationwide</td>
<td>12–15 years</td>
<td>School based</td>
<td>1913</td>
<td>0.8% (0.4% – 1.2%)</td>
<td>MoH HOK 2011</td>
</tr>
</tbody>
</table>

**WHO verification**

- **Status of verifying prevalence targets**
  - Verification started: February 2011
  - Decision: <1% in children
  - Decision date: July 2011

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: UN, UNICEF and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
## Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>Data 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population</td>
<td>567,441</td>
</tr>
<tr>
<td>Births</td>
<td>5714</td>
</tr>
<tr>
<td>Surviving infants</td>
<td>5465</td>
</tr>
<tr>
<td>Urban population</td>
<td>100%</td>
</tr>
</tbody>
</table>

## Hepatitis B vaccine

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>1984</td>
<td>HepB3 introduced nationwide</td>
<td></td>
</tr>
<tr>
<td>1989</td>
<td>HepB birth dose introduced</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Current schedule</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0, 1 months, 6 months</td>
</tr>
<tr>
<td></td>
<td>HepB3 type</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monovalent</td>
</tr>
</tbody>
</table>

## Reported hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Timely HepB BD</th>
<th>HepB3</th>
<th>Any HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>100%</td>
<td>80%</td>
<td>94%</td>
</tr>
<tr>
<td>2009</td>
<td>80%</td>
<td>60%</td>
<td>90%–94%</td>
</tr>
<tr>
<td>2010</td>
<td>60%</td>
<td>40%</td>
<td>80%–89%</td>
</tr>
<tr>
<td>2011</td>
<td>40%</td>
<td>20%</td>
<td>50%–79%</td>
</tr>
<tr>
<td>2012</td>
<td>20%</td>
<td>0%</td>
<td>&lt;50%</td>
</tr>
</tbody>
</table>

## Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD</th>
<th>HepB3</th>
<th>DTP3</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>Nationwide</td>
<td>6–9 years</td>
<td>School based</td>
<td>437</td>
<td>0% (0% – 0.7%)</td>
<td>MoH MAC 2008</td>
</tr>
</tbody>
</table>

## WHO verification

<table>
<thead>
<tr>
<th>Status of verifying prevalence targets</th>
<th>Verification started:</th>
<th>Decision:</th>
<th>Decision date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verification started:</td>
<td>April 2008</td>
<td>&lt;1% in children</td>
<td>August 2008</td>
</tr>
</tbody>
</table>

### Abbreviations:
- DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

### Sources:
- UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

<table>
<thead>
<tr>
<th>Statistic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2012)</td>
<td>20,528</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>292</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>290</td>
</tr>
<tr>
<td>Urban population (2012)</td>
<td>75%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

<table>
<thead>
<tr>
<th>Statistic</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3 introduced nationwide</td>
<td>1989</td>
</tr>
<tr>
<td>HepB birth dose introduced</td>
<td>n.a.</td>
</tr>
<tr>
<td>Current schedule</td>
<td>0, 6 weeks, 3 months, 5 months</td>
</tr>
<tr>
<td>HepB3 type</td>
<td>DTP-Hib-HepB</td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Districts by coverage categories*

<table>
<thead>
<tr>
<th>Coverage Category</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50%</td>
<td>0</td>
</tr>
<tr>
<td>50%-79%</td>
<td>0</td>
</tr>
<tr>
<td>80%-89%</td>
<td>0</td>
</tr>
<tr>
<td>90%-94%</td>
<td>0</td>
</tr>
<tr>
<td>&gt;94%</td>
<td>100%</td>
</tr>
</tbody>
</table>

### Neonatal deliveries

- Health facility: 99.60%
- Home with SBA: 0.40%
- Home with no SBA: 0%
- Unknown: 0%

### Reported hepatitis B vaccination coverage

![Graph showing vaccination coverage from 2008 to 2012](image)

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>School based</td>
<td>265</td>
<td>0%</td>
<td>PRELIMINARY DATA</td>
</tr>
</tbody>
</table>

### WHO verification

- Status of verifying prevalence targets:
  - Verification started: October 2011
  - Decision: n.a.
  - Decision date: n.a.

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** UN, UNICEF, and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DTP3 coverage.
FIJI

Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>875,822</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>18,201</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>18,080</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>52%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>not reported</td>
<td>not reported</td>
<td>439</td>
<td>86%</td>
<td>99%</td>
<td>not reported</td>
<td>Confirm data with country</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12–24 months</td>
<td>Hospital based</td>
<td>285</td>
<td>0.7%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2008</td>
<td>Sub-national</td>
<td>6 months–5 years</td>
<td>Community based</td>
<td>428</td>
<td>0%</td>
<td>WHO:RS/2009/GE/23(JPN)</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Abbreviations:
- DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- Sources: UN, UNICEF and WHO
- HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

- Total Population (2012): 276,731
- Births (2012): 4,562
- Surviving infants (2012): 4,543
- Urban Population (2012): 51%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1992
- HepB birth dose introduced: not reported
- Current schedule: 0, 1 months, 6 months
- HepB3 type: Monovalent

Neonatal deliveries

- 1.00% (99.00%)

Reported hepatitis B vaccination coverage

- 2008: 99%
- 2009: 99%
- 2010: 99%
- 2011: 99%
- 2012: 99%

Districts by coverage categories*

- <50%
- 50%–79%
- 80%–89%
- 90%–94%
- >94%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Austral Island</td>
<td>0–11 months</td>
<td>Community based</td>
<td>957</td>
<td>2.1%</td>
<td>B Trans R Soc Trop 1990</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
GUAM

Demographics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>184,334</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Births (2012)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,249</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,209</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>93%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB birth dose introduced: not reported
- Current schedule: 0, 2 months, 4 months, 6 months, 12 months
- HepB3 type: DTP-Hib-HepB

Neonatal deliveries

- Health facility: 0.60%
- Home with SBA: 12.20%
- Home with no SBA: 87.22%
- Unknown: 0%

Reported hepatitis B vaccination coverage

- Timely HepB BD
- HepB3
- Any HepB BD

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

WHO verification

Status of verifying prevalence targets

- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: UN, UNICEF and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Hepatitis B vaccine

- HepB3 introduced nationwide: not reported
- HepB birth dose introduced: not reported
- Current schedule: if HBsAg+ mother
- HepB3 type: Monovalent

Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>126,434,653</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>1,068,161</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>1,070,409</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>67%</td>
</tr>
</tbody>
</table>

Neonatal deliveries

- Health facility: 99.77%
- Home with SBA: 0.18%
- Home with no SBA: 0.05%
- Unknown: 0.08%

Reported hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>Okinawa</td>
<td>1–4 years</td>
<td>School based</td>
<td>1529</td>
<td>0.1%</td>
<td></td>
<td>Hayashi Int J Epi 1990</td>
</tr>
<tr>
<td>1995–1996</td>
<td>Nationwide</td>
<td>16–19 years</td>
<td>Blood Donors</td>
<td>10,787</td>
<td>0.4%</td>
<td>0.4%–0.5%</td>
<td>Furusyo AMTM 1999</td>
</tr>
<tr>
<td>1995–2000</td>
<td>Nationwide</td>
<td>16–19 years</td>
<td>Blood Donors</td>
<td>58,241</td>
<td>0.23%</td>
<td>0.22%–0.24%</td>
<td>Tanaka Interviro 2004</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95% CI) | Reference/Notes |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>Okinawa</td>
<td>1–4 years</td>
<td>School based</td>
<td>1529</td>
<td>0.1%</td>
<td>Hayashi Int J Epi 1990</td>
</tr>
<tr>
<td>1995–1996</td>
<td>Nationwide</td>
<td>16–19 years</td>
<td>Blood Donors</td>
<td>10,787</td>
<td>0.4% (0.4% – 0.5%)</td>
<td>Furusyo AMTM 1999</td>
</tr>
<tr>
<td>1995–2000</td>
<td>Nationwide</td>
<td>16–19 years</td>
<td>Blood Donors</td>
<td>58,241</td>
<td>0.23% (0.22% – 0.24%)</td>
<td>Tanaka Interviro 2004</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: UN, UNICEF and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
KIRIBATI

Demographics

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>102,660</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>1229</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>1226</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>48%</td>
</tr>
</tbody>
</table>

Vaccination coverage (%)

- 2012: 81.85%
- 2011: 16.40%
- 2010: 1.75%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1995
- HepB birth dose introduced: 1990
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Neonatal deliveries

- Health facility: 16.40%
- Home with SBA: 1.75%
- Home with no SBA: 81.85%

Reported hepatitis B vaccination coverage

- Timely HepB BD
- HepB3
- Any HepB BD

Districts by coverage categories

- <50%
- 50%-79%
- 80%-89%
- 90%-94%
- >94%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD</th>
<th>HepB3</th>
<th>DTP3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12–24 months</td>
<td>Hospital based</td>
<td>156</td>
<td>3.8%</td>
<td>Wilson Vaccine 2000</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: UN, UNICEF and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>6,373,934</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>139,845</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>135,845</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>33%</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 2001
- HepB birth dose introduced: ~2005
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

**Neonatal deliveries**

- Health facility: 81.50%
- Home with SBA: 5.70%
- Home with no SBA: 12.80%
- Unknown: 0%

**Reported hepatitis B vaccination coverage**

<table>
<thead>
<tr>
<th>Year</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>12 months</td>
<td>828</td>
<td>not reported</td>
<td>not reported</td>
<td>32%</td>
<td>MICS; 41.3% HepB3 by 23M</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>5–9 years</td>
<td>Community based</td>
<td>1008</td>
<td>1.5%</td>
<td>PRELIMINARY DATA</td>
</tr>
</tbody>
</table>

**WHO verification**

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
MALAYSIA

Demographics

- Births (2012): 581,991
- Surviving infants (2012): 575,324
- Urban Population (2012): 72%

Vaccination coverage (%)

- Timely HepB BD
- HepB3

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 1 months, 6 months
- HepB3 type: Monovalent

Neonatal deliveries

- Health facility: 98.12%
- Home with SBA: 0.53%
- Home with no SBA: 1.35%
- Unknown: 0%

Reported hepatitis B vaccination coverage

- 2008: 80%
- 2009: 80%
- 2010: 80%
- 2011: 80%
- 2012: 80%

Districts by coverage categories*

- <50%
- 50%-79%
- 80%-89%
- 90%-94%
- >94%

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
1997–2007 | Nationwide | 6–9 years | School based | 193717 | 0.4% | MoH Malaysia 2011
2009 | Nationwide | 9 years | School based | 2928 | 0.2% [0%–0.3%] | MoH Malaysia 2011
2009 | Nationwide | 10 years | School based | 3265 | 0.4% [0.2%–0.6%] | MoH Malaysia 2011

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence [95% CI] | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
1997–2007 | Nationwide | 6–9 years | School based | 193717 | 0.4% | MoH Malaysia 2011
2009 | Nationwide | 9 years | School based | 2928 | 0.2% [0%–0.3%] | MoH Malaysia 2011
2009 | Nationwide | 10 years | School based | 3265 | 0.4% [0.2%–0.6%] | MoH Malaysia 2011

WHO verification

- Verification started: March 2011
- Decision: <1% in children
- Decision date: July 2011

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: UN, UNICEF, and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>55,717</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>1,301</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>1,287</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>72%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1990s
- HepB birth dose introduced: 1998
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-HepB-IPV

Vaccination coverage (%)

<table>
<thead>
<tr>
<th>Year</th>
<th>Timely HepB BD</th>
<th>HepB3</th>
<th>Any HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Neonatal deliveries

- 20.00% at Health facility
- 1.00% Home with SBA
- 97.00% Home with no SBA
- 0.00% Unknown

Reported hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Vaccination coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
</tr>
</tbody>
</table>

Districts by coverage categories*

- >94%
- 90%–94%
- 80%–89%
- 50%–79%
- <50%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Majuro, Ebeye</td>
<td>5–9 years</td>
<td>331</td>
<td>49%</td>
<td>93%</td>
<td>not reported</td>
<td>Bialek Ped Infect Dis 2010</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Majuro, Ebeye</td>
<td>5–9 years</td>
<td>School based</td>
<td>331</td>
<td>1.8% (0.4% – 3.3%)</td>
<td>Bialek PID 2010</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets: pending
- Verification started: n.a.
- Decision: n.a.
- Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
FEDERATED STATES OF MICRONESIA

### Demographics
- **Total Population (2012)**: 112,098
- **Births (2012)**: 2,725
- **Surviving infants (2012)**: 2,656
- **Urban Population (2012)**: 23%

### Hepatitis B vaccine
- HepB3 introduced nationwide: not reported
- HepB birth dose introduced: not reported
- **Current schedule**: 0, 2 months, 6 months
- HepB3 type: Monovalent

### Neonatal deliveries
- Health facility: 80.00%
- Home with SBA: 20.00%
- Home with no SBA: 0.00%
- Unknown: 0.00%

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>National</td>
<td>2 years</td>
<td>16391</td>
<td>not reported</td>
<td>84%</td>
<td>not reported</td>
<td>Manea PH Reports 1992</td>
</tr>
<tr>
<td>1992</td>
<td>Chuuk</td>
<td>2 years</td>
<td>544</td>
<td>not reported</td>
<td>40%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>1994</td>
<td>Pohnpei</td>
<td>3–4 years</td>
<td>364</td>
<td>not reported</td>
<td>82%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Chuuk</td>
<td>2–6 years</td>
<td>Hospital based</td>
<td>362</td>
<td>2.5%</td>
<td>Bialek PID 2010</td>
</tr>
</tbody>
</table>

### WHO verification
- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: UN, UNICEF and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1991
- HepB birth dose introduced: not reported
- Current schedule: 0, 2 months, 3 months, 4 months
- HepB3 type: DTP-Hib-HepB

**Demographics**

- Total Population (2012): 2,844,081
- Births (2012): 65,650
- Surviving infants (2012): 63,424
- Urban Population (2012): 63%

**Neonatal deliveries**

- 99.51% at Health facility
- 0.20% at Home with SBA
- 0.20% at Home with no SBA

**Reported hepatitis B vaccination coverage**

- Timely HepB BD: >94%
- HepB3: 90%–94%
- Any HepB BD: 80%–89%
- DTP3: 50%–79%

**Districts by coverage categories***

<table>
<thead>
<tr>
<th>%</th>
<th>Districts 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;94%</td>
<td>25</td>
</tr>
<tr>
<td>90%–94%</td>
<td>25</td>
</tr>
<tr>
<td>80%–89%</td>
<td>5</td>
</tr>
<tr>
<td>50%–79%</td>
<td>5</td>
</tr>
<tr>
<td>&lt;50%</td>
<td>0</td>
</tr>
</tbody>
</table>

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD</th>
<th>HepB3</th>
<th>DTP3</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>Urban Area</td>
<td>2 years</td>
<td>127</td>
<td>not reported</td>
<td>94%</td>
<td>not reported</td>
<td>Edstam Prev Med 2002</td>
</tr>
<tr>
<td>1999</td>
<td>Rural</td>
<td>2 years</td>
<td>148</td>
<td>not reported</td>
<td>76%</td>
<td>not reported</td>
<td>Edstam Prev Med 2002</td>
</tr>
<tr>
<td>2004</td>
<td>National</td>
<td>8 years</td>
<td>1145</td>
<td>65%</td>
<td>60%</td>
<td>not reported</td>
<td>Davaalkham J Epid 2007</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>Nationwide</td>
<td>7–12 years</td>
<td>School based</td>
<td>1145</td>
<td>5.2%</td>
<td>Davaalkham PI 2007</td>
</tr>
<tr>
<td>2009</td>
<td>Nationwide</td>
<td>4 years</td>
<td>Community based</td>
<td>5894</td>
<td>0.34%</td>
<td>MoH Mongolia 2011</td>
</tr>
</tbody>
</table>

**WHO verification**

- Verification started: April 2012
- Decision: <1% in children
- Decision date: July 2012

**Abbreviations**

- DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.

**Sources**

- UN
- UNICEF
- WHO
### NAURU

#### Demographics
- Total Population (2012): 10,370
- Births (2012): 365
- Surviving infants (2012): 361
- Urban Population (2012): 100%

#### Hepatitis B vaccine
- HepB3 introduced nationwide: 1983
- HepB birth dose introduced: not reported
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

#### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

#### Reported hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Timely HepB BD</th>
<th>HepB3</th>
<th>Any HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>97.40%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Districts by coverage categories*

- <50%: 0
- 50%–79%: 0
- 80%–89%: 0
- 90%–94%: 1
- >94%: 0

---

### Neonatal deliveries

- 97.40%

### Vaccination coverage surveys

#### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

#### WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

---

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

- Total Population (2012): 258,735
- Births (2012): 4,157
- Surviving infants (2012): 4,140
- Urban Population (2012): 57%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1998 (for HBsAg+ moms)
- Current schedule: 0, 1 months, 6 months
- HepB3 type: Monovalent

### Neonatal deliveries

- Health facility: 87.60%
- Home with SBA: 4.37%
- Home with no SBA: 8.03%
- Unknown: 4.37%

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Reported hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Timely HepB BD</th>
<th>HepB3</th>
<th>Any HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>100</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Districts by coverage categories*

<table>
<thead>
<tr>
<th>Coverage Category</th>
<th>Districts 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50%</td>
<td></td>
</tr>
<tr>
<td>50%–79%</td>
<td></td>
</tr>
<tr>
<td>80%–89%</td>
<td></td>
</tr>
<tr>
<td>90%–94%</td>
<td></td>
</tr>
<tr>
<td>&gt;94%</td>
<td></td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### WHO verification

Status of verifying prevalence targets
- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**NEW ZEALAND**

### Hepatitis B vaccine
- HepB3 introduced nationwide: 1985
- HepB birth dose introduced: not reported
- Current schedule: 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB-IPV

### Demographics
- Total Population (2012): 4,461,257
- Births (2012): 64,499
- Surviving infants (2012): 64,075
- Urban Population (2012): 86%

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>12 months</td>
<td>1,563</td>
<td>72%</td>
<td>82%</td>
<td>85%</td>
<td>MoH; 87% HepB3 by 2Y</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>North Islands</td>
<td>6 years</td>
<td>Community based</td>
<td>466</td>
<td>0.2% (0.0% – 1.2%)</td>
<td>Weir R. MoH NEZ 2009</td>
</tr>
</tbody>
</table>

### WHO verification
- Verification started: April 2012
- Decision: <1% in children
- Decision date: September 2012

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

- Total Population (2012): 1385
- Births (2012): 25
- Surviving infants (2012): 25
- Urban Population (2012): 38%

### Hepatitis B vaccine

- HepB3 introduced nationwide: not reported
- HepB birth dose introduced: not reported
- Current schedule: 0, 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB-IPV

### Neonatal deliveries

- 100.0% vaccination coverage (%)

### Reported hepatitis B vaccination coverage

Graph showing vaccination coverage (%)

### Districts by coverage categories*

Graph showing % of districts by coverage categories

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

### WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

---

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
NORTHERN MARIANA ISLANDS

**Demographics**

- Total Population (2012): 62,152
- Births (2012): 1,075
- Surviving infants (2012): 1,067
- Urban Population (2012): 91%

**Health facility Vaccination coverage (%):**

- 100.0%

**Home with SBA**

- 0%

**Home with no SBA**

- 20%

**Unknown**

- 40%

**60%

**80%

**100%

**Timely HepB BD**

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 6 weeks, 6 months
- HepB3 type: DTP-HepB-IPV

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 6 weeks, 6 months
- HepB3 type: DTP-HepB-IPV

**Neonatal deliveries**

- Health facility
- Home with SBA
- Home with no SBA
- Unknown

**Reported hepatitis B vaccination coverage**

<table>
<thead>
<tr>
<th>Year</th>
<th>HepB3</th>
<th>HepB3</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>94%</td>
<td>90%</td>
</tr>
<tr>
<td>2009</td>
<td>93%</td>
<td>88%</td>
</tr>
<tr>
<td>2010</td>
<td>92%</td>
<td>87%</td>
</tr>
<tr>
<td>2011</td>
<td>91%</td>
<td>86%</td>
</tr>
<tr>
<td>2012</td>
<td>90%</td>
<td>85%</td>
</tr>
</tbody>
</table>

**Districts by coverage categories***

- 0% – 50%
- 50% – 79%
- 80% – 89%
- 90% – 94%
- >94%

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>National</td>
<td>3–4 years</td>
<td>200</td>
<td>not reported</td>
<td>94%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>19–35 months</td>
<td>295</td>
<td>100%</td>
<td>94%</td>
<td>not reported</td>
<td>not reported</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1994</td>
<td>Saipan</td>
<td>3–4 years</td>
<td>Health facility</td>
<td>200</td>
<td>0.5%</td>
<td>Durand Pac Hth Dial 1996</td>
</tr>
</tbody>
</table>

**WHO verification**

<table>
<thead>
<tr>
<th>Status of verifying prevalence targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verification started: pending</td>
</tr>
<tr>
<td>Decision: n.a.</td>
</tr>
<tr>
<td>Decision date: n.a.</td>
</tr>
</tbody>
</table>

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: UN, UNICEF and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>20,758</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>269</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>266</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>83%</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 6 weeks, 4 months, 6 months
- HepB3 type: DTP-HepB-IPV

**Neonatal deliveries**

- 100.0% vaccination coverage

**Reported hepatitis B vaccination coverage**

<table>
<thead>
<tr>
<th>Year</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>100</td>
<td>85</td>
<td>not reported</td>
</tr>
<tr>
<td>2009</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Districts by coverage categories**

<table>
<thead>
<tr>
<th>Coverage Category</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50%</td>
<td></td>
</tr>
<tr>
<td>50%–79%</td>
<td></td>
</tr>
<tr>
<td>80%–89%</td>
<td></td>
</tr>
<tr>
<td>90%–94%</td>
<td></td>
</tr>
<tr>
<td>&gt;94%</td>
<td></td>
</tr>
</tbody>
</table>

**Vaccination coverage surveys**

- Survey year: 2003
- Location: National
- Ages enrolled: 10–11 years
- Sample size: 192
- HepB BD: 100%
- HepB3: 85%
- DTP3: not reported
- Reference/Notes: Bialek ISVHLD P351 2006

**Hepatitis B serological surveys**

- Survey year: 2003
- Location: Nationwide
- Ages enrolled: 10–11 years
- Sampling base: Community based
- Sample size: 192
- HBsAg prevalence (95% CI): 0%
- Reference/Notes: Bialek ISVHLD P351 2006

**WHO verification**

- Status of verifying prevalence targets
- Verification started: January 2013
- Decision: <1% in children
- Decision date: May 2013

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
PAPUA NEW GUINEA

Demographics

- Births (2012): 209,788
- Surviving infants (2012): 200,631
- Urban Population (2012): 13%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: ~ 2005
- Current schedule: 0, 1 months, 2 months, 3 months
- HepB3 type: DTP-Hib-HepB

Reported hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>HepB3</th>
<th>Any HepB</th>
<th>DPT3</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>94%</td>
<td>90%–94%</td>
<td>80%–89%</td>
</tr>
<tr>
<td>2011</td>
<td>94%</td>
<td>90%–94%</td>
<td>90%–94%</td>
</tr>
<tr>
<td>2010</td>
<td>94%</td>
<td>90%–94%</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>2009</td>
<td>94%</td>
<td>90%–94%</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>2008</td>
<td>94%</td>
<td>90%–94%</td>
<td>&gt;94%</td>
</tr>
</tbody>
</table>

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD</th>
<th>HepB3</th>
<th>DPT3</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989–1990</td>
<td>Port Moresby</td>
<td>3–5 months</td>
<td>Hospital based</td>
<td>31</td>
<td>13%</td>
<td>NembA TPaed. 1993</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets: pending
- Decision started: n.a.
- Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Health facility**

- **Home with SBA**
- **Home with no SBA**
- **Unknown**

<table>
<thead>
<tr>
<th>Vaccination coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>44.0%</td>
</tr>
<tr>
<td>18.20%</td>
</tr>
<tr>
<td>37.80%</td>
</tr>
</tbody>
</table>

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>12–24 months</td>
<td>1348</td>
<td>not reported</td>
<td>NR</td>
<td>79</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2008</td>
<td>National</td>
<td>12–24 months</td>
<td>1286</td>
<td>not reported</td>
<td>80.3</td>
<td>NR</td>
<td>DHS Survey</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: UN, UNICEF and WHO

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

<table>
<thead>
<tr>
<th>Total Population (2012)</th>
<th>48 588 326</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2012)</td>
<td>480,099</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>477,779</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>83%</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1983
- HepB birth dose introduced: 1983
- Current schedule: 0, 1 month, & 6 months
- HepB3 type: Monovalent

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>National</td>
<td>0–6 years</td>
<td>1026</td>
<td>100%</td>
<td>93%</td>
<td>94.7%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>0–3 years</td>
<td>7040</td>
<td>99%</td>
<td>98%</td>
<td>93.4%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence [95% CI]</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Nationwide</td>
<td>10–14 years</td>
<td>Community based</td>
<td>594</td>
<td>0.2% (0.0% – 0.6%)</td>
<td>CDC Korea 2008</td>
</tr>
<tr>
<td>2007</td>
<td>Nationwide</td>
<td>4–6 years</td>
<td>Hospital based</td>
<td>2920</td>
<td>0.2% (0.0% – 0.4%)</td>
<td>CDC Korea 2008</td>
</tr>
</tbody>
</table>

**WHO verification**

- Status of verifying prevalence targets:
  - Verification started: January 2008
  - Decision: <1% in children
  - Decision date: June 2008

**Abbreviations:**

- DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAG: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.

---

**Neonatal deliveries**

- Health facility: 0.10%
- Home with SBA: 99.90%
- Home with no SBA: 99.90%
- Unknown: 99.90%

**Reported hepatitis B vaccination coverage**

<table>
<thead>
<tr>
<th>Year</th>
<th>Timely HepB BD</th>
<th>HepB3</th>
<th>Any HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Districts by coverage categories**

- >94%
- 90%–94%
- 80%–89%
- 50%–79%
- <50%

---

**Sources:**

- UN, UNICEF and WHO
**Demographics**

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>184,772</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>4408</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>4375</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>20%</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: ~2005
- HepB3 type: DTP-Hib-HepB
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks

**Neonatal deliveries**

- Health facility: 81.00%
- Home with SBA: 19.00%
- Home with no SBA: 0%
- Unknown: 0%

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>12–24 months</td>
<td>321</td>
<td>70%</td>
<td>not reported</td>
<td>not reported</td>
<td>DHS Survey</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

**WHO verification**

<table>
<thead>
<tr>
<th>Status of verifying prevalence targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verification started:</td>
</tr>
<tr>
<td>Decision:</td>
</tr>
<tr>
<td>Decision date:</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
SINGAPORE

Demographics

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>5,256,278</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>48,522</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>46,946</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>100%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1985
- HepB birth dose introduced: 1987
- Current schedule: 0, 1 months, 5 months
- HepB3 type: Monovalent

Vaccination coverage (%)

- 2012: 99.74%
- 2011: 0.26%

Timely HepB BD

- 2012: >94%
- 2011: 90%–94%
- 2010: 80%–89%
- 2009: 50%–79%
- 2008: <50%

Abreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: UN, UNICEF and WHO

Hepatitis B serological surveys

- 1998–1999: National, 0–4 years, not reported, 229, 0% (95% CI), Epi News Bull SNG 2000

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics
- Total Population (2012): 566,481
- Births (2012): 17,414
- Surviving infants (2012): 16,761
- Urban Population (2012): 19%

### Hepatitis B vaccine
- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: ~2005
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

### Neonatal deliveries
- Health facility: 85.00%
- Home with SBA: 1.00%
- Home with no SBA: 14.00%
- Unknown: 0%

### Reported hepatitis B vaccination coverage
- Vaccination coverage (%)
  - 2008: 94%
  - 2009: 90%
  - 2010: 94%
  - 2011: 80%
  - 2012: 79%

### Districts by coverage categories*
- 2012
  - Timely HepB BD
  - HepB3
  - Any HepB BD
  - >94%
  - 90%-94%
  - 80%-89%
  - 50%-79%
  - <50%

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Timely HepB BD</td>
<td>Any HepB BD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>Guadalcanal Islands</td>
<td>0–9 years</td>
<td>Hospital based</td>
<td>115</td>
<td>13%</td>
<td>Furusyo Am J Trop 1999</td>
</tr>
</tbody>
</table>

### WHO verification
- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: UN, UNICEF and WHO

1 HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
TOKELAU

Demographics
- Total Population (2012): 1136
- Births (2012): 18
- Surviving infants (2012): 21
- Urban Population (2012): 0%

Hepatitis B vaccine
- HepB3 introduced nationwide: not reported
- HepB birth dose introduced: not reported
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Neonatal deliveries

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
---|---|---|---|---|---|---|---

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95% CI) | Reference/Notes
---|---|---|---|---|---|---

WHO verification

Status of verifying prevalence targets
- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: UN, UNICEF and WHO

1 HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

- **Total Population (2012)**: 104,891
- **Births (2012)**: 2,731
- **Surviving infants (2012)**: 2,724
- **Urban Population (2012)**: 23%

### Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: not reported
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Tongatapu hospital</td>
<td>6–59 months</td>
<td>445</td>
<td>92%</td>
<td>98%</td>
<td>98%</td>
<td>Danielsson Vaccine 2009</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12–24 months</td>
<td>Hospital based</td>
<td>211</td>
<td>3.8%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2005</td>
<td>Main Island</td>
<td>6–59 months</td>
<td>Hospital based</td>
<td>375</td>
<td>0.8% (0.2% – 2.5%)</td>
<td>Danielsson Vaccine 2009</td>
</tr>
</tbody>
</table>

### WHO verification

- **Status of verifying prevalence targets**
  - Verification started: May 2011
  - Decision: <2% in children
  - Decision date: January 2012

### Abbreviations

- DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

### Notes

- HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.

---

**Sourc**es: UN, UNICEF and WHO
TUVALU

Demographics
- Total Population (2012): 9,867
- Births (2012): 277
- Surviving infants (2012): 277
- Urban Population (2012): 50%

Hepatitis B vaccine
- HepB3 introduced nationwide: not reported
- HepB birth dose introduced: not reported
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Demographics
- Neonatal deliveries
- Vaccination coverage surveys
- Reported hepatitis B vaccination coverage
- Districts by coverage categories*

Vaccination coverage surveys
- Survey year
- Location
- Ages enrolled
- Sample size
- HepB BD %
- HepB3 %
- DTP3 %
- Reference/Notes

Hepatitis B serological surveys
- Survey year
- Location
- Ages enrolled
- Sampling base
- Sample size
- HBsAg prevalence (95% CI)
- Reference/Notes

WHO verification
- Status of verifying prevalence targets
- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: UN, UNICEF and WHO
* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

- Total Population (2012): 251,674
- Births (2012): 7274
- Surviving infants (2012): 7019
- Urban Population (2012): 26%

### Hepatitis B vaccine

- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>13 months</td>
<td>359</td>
<td>not reported</td>
<td>59%</td>
<td>58%</td>
<td>MICS; 55.3% HepB3 by 23M</td>
</tr>
</tbody>
</table>

### Neonatal deliveries

- Health facility: 80.0%
- Home with SBA: 20.0%
- Home with no SBA: 0.0%
- Unknown: 0.0%

### Reported hepatitis B vaccination coverage

- Timely HepB BD
- HepB3
- Any HepB BD

### Districts by coverage categories*

- <50%
- 50%–79%
- 80%–89%
- 90%–94%
- >94%

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAG prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12–24 months</td>
<td>Hospital based</td>
<td>132</td>
<td>3.0%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>1998</td>
<td>Emao or Nguna</td>
<td>12–18 months</td>
<td>Community based</td>
<td>112</td>
<td>17%</td>
<td>Maher Med J Aust 1991</td>
</tr>
</tbody>
</table>

### WHO verification

- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.

**Sources:** UN, UNICEF and WHO
VIET NAM

Neonatal deliveries

[Diagram showing vaccination coverage]

Demographics

<table>
<thead>
<tr>
<th>Total Population (2012)</th>
<th>89,730,274</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2012)</td>
<td>1,444,753</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>1,433,094</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>30%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1997
- HepB birth dose introduced: 2005
- Current schedule: 0, 2 months, 3 months, 4 months
- HepB3 type: DTP-Hib-HepB

Reported hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>HepB BD (%)</th>
<th>HepB3 (%)</th>
<th>DPT3 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Districts by coverage categories*

[Graph showing coverage percentages]

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DPT3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>National</td>
<td>12–24 months</td>
<td>457</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2006</td>
<td>National</td>
<td>12 months</td>
<td>555</td>
<td>not reported</td>
<td>32%</td>
<td>76%</td>
<td>MICS; 33.9% HepB3 by 23M</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Thanh Hoa</td>
<td>9–18 months</td>
<td>Community based</td>
<td>536</td>
<td>12.5%</td>
<td>Hipgrave AJTMH 2003</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>3–4 years</td>
<td>Community based</td>
<td>3426</td>
<td>1.6%</td>
<td>PRELIMINARY DATA</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>5–7 years</td>
<td>Community based</td>
<td>1738</td>
<td>2.10%</td>
<td>PRELIMINARY DATA</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: UN, UNICEF and WHO

1 HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2012)</td>
<td>13,348</td>
</tr>
<tr>
<td>Births (2012)</td>
<td>1,828</td>
</tr>
<tr>
<td>Surviving infants (2012)</td>
<td>1,777</td>
</tr>
<tr>
<td>Urban Population (2012)</td>
<td>0%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

- HepB3 introduced nationwide: not reported
- HepB birth dose introduced: not reported
- Current schedule: 0, 2 months, 3 months, 4 months, 16 months
- HepB3 type: DTP-HepB-IPV

### Neonatal deliveries

![Image of a neonatal delivery with 100.0% coverage]

### Reported hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Districts by coverage categories*

- <50%
- 50%–79%
- 80%–89%
- 90%–94%
- >94%

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>7–12 years</td>
<td>442</td>
<td>not reported</td>
<td>94%</td>
<td>not reported</td>
<td>Data from national serosurvey</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>National</td>
<td>7–12 years</td>
<td>School-based</td>
<td>469</td>
<td>0.4% [0% – 1.0%]</td>
<td>PRELIMINARY DATA</td>
</tr>
</tbody>
</table>

### WHO verification

- Status of verifying prevalence targets: pending
- Verification started: n.a.
- Decision: n.a.
- Decision date: n.a.

---

**Abbreviations:**  
DTP3: 3rd dose of Diphtheria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours  
**Sources:** UN, UNICEF and WHO

* HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.